Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 131

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 131
---
 if it has not been completed (we refer to these services as the “Transition
Services”).

To the extent that a Transition Services Agreement is not executed prior to the completion of the Divestiture, the Divestiture Agreement
provides that for a period not to exceed six months following the date of the completion of the Divestiture, Aadi must use its commercially reasonable efforts to provide the Transition Services as reasonably determined by Aadi, and provided that
such Transition Services are not of such scope that they would materially interfere with the performance by employees of Aadi of their ordinary responsibilities to Aadi.

Kaken has agreed to (1) use its reasonable best efforts to, prior to and in any event as promptly as practicable following the date of the completion of
the Divestiture, transition the Transition Services to its own internal organization or obtain alternate third-party sources to provide such services and reduce, limit and ultimately end its reliance on the Transition Services provided under the
Divestiture Agreement, and (2) ensure it has sufficient resources available to it at the end of the provision of any such Transition Services to perform the Transition Services (or have the Transition Services performed) without the involvement
of Aadi, its affiliates or any of its or their employees or agents.

Non-Competitionand Non-Solicitation

The Divestiture Agreement contains certain restrictions and covenants with respect to
protecting the legitimate business interests of Aadi Sub and Kaken following the completion of the Divestiture. Aadi has agreed on its own behalf and on behalf of its subsidiaries that, subject to certain exceptions set forth in the Divestiture
Agreement, from the date of the completion of the Divestiture to the fourth anniversary thereof (which we refer to as the “Restricted Period”), Aadi will not, and will not permit any of its subsidiaries to, directly or indirectly, anywhere
in any country or territory where the FYARRO Business has been or is currently proposed to be conducted by Aadi or any of Aadi’s controlled affiliates (which we refer to as the “Restricted Territory”), research, develop, manufacture,
commercialize or otherwise exploit another therapeutic product intended for the treatment of PEComa.

Aadi also has agreed on its own behalf and on behalf
of its subsidiaries that, subject to certain exceptions set forth in the Divestiture Agreement, during the Restricted Period, it will not, and will not permit its subsidiaries to, directly or indirectly, anywhere in the Restricted Territory, whether
as